(Q46113435)

English

JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients

scientific article published in February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

0 references

Nicola Polverelli

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

object named as

Lucia Catani

4

0 references

Francesca Palandri

object named as

Francesca Palandri

1

0 references

Giovanni Martinelli

7

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

Michele Baccarani

8

object named as

Michele Baccarani

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

Emanuela Ottaviani

2

object named as

Emanuela Ottaviani

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

Mauro Fiacchini

6

object named as

Mauro Fiacchini

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

3

object named as

Federica Salmi

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

author name string

Nicola Vianelli

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

language of work or name

0 references

publication date

1 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

50

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

247-253

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

Essential thrombocythaemia: challenges and evidence-based management

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

A long-term retrospective study of young women with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Efficacy and safety of low-dose aspirin in polycythemia vera

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

The myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1080%2F10428190802688152

21 January 2018

Identifiers

10.1080/10428190802688152

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19235016

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46113435&oldid=2093251234"